ADDIS ABABA – Alliance Global Group (AGBL), a Dubai-based biomedical company, has announced that the Group’s wing in Ethiopia, AGBL Abyssinia, has become fully operational to deliver novel biomedical products and technologies including Next Generation Sequencing (NGS) to the Ethiopian and Northeast African market.
Ethiopia’s central location, large population and abundant resources, allied to its rich history and present political stability and social policies make it a strategically important player in the region and ideal location for AGBL to establish its presence, dubbed AGBL Abyssinia.
The rich ethnic and cultural diversity of Ethiopia also provides an opportunity to understand the level to which cultural factors correlate and shape genetic structure in human populations, and makes it an ideal location for AGBL’s ongoing engagement with cutting-edge genetic research.
The AGBL Abyssinia launch event took place on 11 December 2019 at the Addis Ababa Hyatt Regency and was attended by Jemal Beker Abedula, State Minister of Innovation and Technology, Dr, Kassahun Tesfaye, Director General of the Ethiopian Biotechnology Institute (EBTi), Dr, Tamer Degheidy, AGBL Chief Executive Officer, Rodolphe Vetchenou, Illumina Executive Territory Manager, and other dignitaries.
AGBL keynote speakers addressed corporate overview of the AGBL Group, next generation sequencing solutions and introduced the audience to Illumina’s benchtop sequencer – the iSeq 100 system. AGBL also celebrated the establishment of its training lab at EBTi and there was an official signing of a memorandum of understanding between AGBL Group and EBTi.
Dr.Tamer Degheidy, expressed his delight at the cooperation, “Africa is a developing market and Ethiopia is well placed to lead it in science and technology, especially in the area of genomic-genetic research.”
About Alliance Global Group (AGBL)
Alliance Global FZ LLC is biomedical technology oriented business group working in such emerging markets as the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group employs more than 80 specialists and has regional offices offering distribution, consulting and product development services to more than 40 quality manufacturers of biomedical technologies. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products.
Source: AGBL